Scientists at BRL, initially in trained animals in the 1970s and 80s, investigated the quantitative EEG and ERP effects of drugs which were agonists, antagonists, precursors of neurotransmitters as well as newly emerging psychotropic drugs. Over the past two decades BRLs neuropharmacological studies have been focused on research in humans directed at the effects on the brain of psychotropic medications and substance abuse.
Using QEEG features, electrophysiological subtypes have been identified in patients considered to be symptomatically homogeneous and who share the same clinical diagnosis. Subtype membership has been demonstrated to be related to pharmocological treatment outcome in a number of disorders, including Attention Deficit Hyperactivity Disorder (ADHD), Major Affective Disorder and Obsessive Compulsive Disorder (OCD). In these studies the hypothesis that the pharmacological treatment which moves the QEEG in the direction of normal will be the most effective has been demonstrated by us and replicated by others.
Current studies include attempts at aggressive interventions to re-establish normal brain homeostasis in patients who persistently remain in a minimally conscious state and in children with Autistic Spectrum Disorder.